A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2016
At a glance
- Drugs JNJ 55375515 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Dec 2016 Status changed from recruiting to completed.
- 22 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016.
- 25 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.